CARCINOMA OF THE MAIN HEPATIC DUCT JUNCTION - INDICATIONS, OPERATIVE MORBIDITY AND MORTALITY, AND LONG-TERM SURVIVAL
- 1 September 1990
- journal article
- research article
- Vol. 108 (3) , 495-501
Abstract
Carcinoma of the main hepatic duct junction tends to spread extensively along the hepatic ducts into the liver parenchyma. Therefore extensive resection of the bile ducts combined with hepatic resection is the procedure of choice. Between January 1973 and April 1989, 25 of 50 patients with this type of carcinoma underwent resection, a resectability rate of 50%. One patient died of staphylococcal sepsis on the postoperative day 42 after right trisegmentectomy and resection of the bile ducts, a hospital death rate of 4%. Twenty-four patients were discharged from the hospital. The 5-year actuarial survival rate calculated by the Kaplan-Meier method was 19%. Four patients lived longer than 5 years after surgery; the longest survival was 9 years after right trisegmentectomy and resection of the bile ducts. These four patients had clear margins at the resected bile ducts. This article was designed to clarify the point at issue by presenting our results in terms of indications, operative morbidity and mortality, and long-term survival.This publication has 14 references indexed in Scilit:
- Major Liver Resection for Hilar CholangiocarcinomaAnnals of Surgery, 1988
- Extended right hepatic lobectomy, left hepatic lobectomy, and skeletonization resection for proximal bile duct cancerWorld Journal of Surgery, 1988
- The long-term survival of patients with carcinoma of the main hepatic duct junctionCancer, 1987
- SURGICAL-TREATMENT FOR CARCINOMA AT THE CONFLUENCE OF THE MAJOR HEPATIC DUCTS1986
- SURGICAL-TREATMENT OF HILAR CARCINOMA OF THE BILE-DUCT1986
- AN ANATOMIC INVESTIGATION OF RADICAL RESECTION OF TUMOR IN THE HEPATIC DUCT CONFLUENCE1985
- Adenocarcinoma of the hepatic duct junction. A reappraisal of the histologic criteria of malignancyCancer, 1984
- Carcinoma of the Bifurcation of the Hepatic DuctsArchives of Surgery, 1983
- FOY: [Ethyl -(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. effect on coagulo-fibrinolytic system in comparison with heparin or aprotininThrombosis Research, 1981
- Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatisThe American Journal of Medicine, 1965